Genomic characterization of recurrent high-grade astroblastoma

Cancer Genetics

Volumn 209, Issue 7-8, 2016, Pages 321-330

  Bale, Tejus A ^a   Abedalthagafi, Malak ^a,b,c   Bi, Wenya Linda ^a   Kang, Yun Jee ^b   Merrill, Parker ^a   Dunn, Ian F ^a   Dubuc, Adrian ^a   Charbonneau, Sarah K ^b   Brown, Loreal ^b   Ligon, Azra H ^a   Ramkissoon, Shakti H ^a,b   Ligon, Keith L ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c KING FAHAD MEDICAL CITY   (Saudi Arabia)

Author keywords

aCGH; Astroblastoma; GBM; NGS; SETD2

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; GLIAL FIBRILLARY ACIDIC PROTEIN; ISOCITRATE DEHYDROGENASE 1; LOMUSTINE; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROCARBAZINE; RETINOBLASTOMA PROTEIN; TEMOZOLOMIDE; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR SOX2; VINCRISTINE;

ADJUVANT THERAPY; ADULT; ANAPLASTIC ASTROBLASTOMA; ARTICLE; ASTROBLASTOMA; BRAIN TUMOR; CASE REPORT; CDKN2A GENE; CHROMOSOME 10; CHROMOSOME 18; CHROMOSOME 5; CHROMOSOME 6Q; CHROMOSOME 9; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DEATH; DIFFERENTIAL DIAGNOSIS; EPENDYMOMA; ERG GENE; FEMALE; GENE MUTATION; GENOMICS; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IDH1 GENE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MONOSOMY X; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; NF1 GENE; ONCOGENE MYB; PARIETAL LOBE; PARK2 GENE; PIK3CA GENE; PRIORITY JOURNAL; PROTON THERAPY; PTEN GENE; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; GENE DOSAGE; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HIGH THROUGHPUT SEQUENCING; NEUROEPITHELIOMA; PATHOLOGY; PROCEDURES; TUMOR RECURRENCE;

ADULT; BRAIN NEOPLASMS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE DOSAGE; GENOME-WIDE ASSOCIATION STUDY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, NEUROEPITHELIAL; SEQUENCE ANALYSIS, DNA;

EID: 84989878815     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2016.06.002     Document Type: Article

References (39)

1. 1 Bailey, P.C., Cushing, H., A Classification of Tumours of the Glioma Group on a Histogenetic Basis with a Correlation Study of Prognosis. 1926, Lippincott, Philadelphia.
2. 2 Bailey, P.B., Bucy, P.C., Astroblastomas of the brain. Acta Psychiatr Neurol 5 (1930), 439–461.
3. 3 Bailey, P., Cellular types in primary tumors of the brain. Penfield, W., (eds.) Cytology and Cellular Pathology of the Nervous System, 1932, P. B. Hoeber, New York, 905–951.
4. 4 Bonnin, J.M., Rubinstein, L.J., Astroblastomas: a pathological study of 23 tumors, with a postoperative follow-up in 13 patients. Neurosurgery 25 (1989), 6–13.
5. 5 Louis, D.N.O., Ohgaki, H., Wiestler, O.D., et al. WHO Classification of Tumours of the Central Nervous System. 2016, IARC Press, Lyon.
6. 6 Kubota, T., Hirano, A., Sato, K., et al. The fine structure of astroblastoma. Cancer 55 (1985), 745–750.
7. 7 Husain, A.N., Leestma, J.E., Cerebral astroblastoma: immunohistochemical and ultrastructural features. Case report. J Neurosurg 64 (1986), 657–661.
8. 8 Rubinstein, L.J., Herman, M.M., The astroblastoma and its possible cytogenic relationship to the tanycyte. An electron microscopic, immunohistochemical, tissue- and organ-culture study. Acta Neuropathol 78 (1989), 472–483.
9. 9 Jay, V., Edwards, V., Squire, J., et al. Astroblastoma: report of a case with ultrastructural, cell kinetic, and cytogenetic analysis. Pediatr Pathol 13 (1993), 323–332.
10. 10 Kubota, T., Sato, K., Arishima, H., et al. Astroblastoma: immunohistochemical and ultrastructural study of distinctive epithelial and probable tanycytic differentiation. Neuropathology 26 (2006), 72–81.
11. 11 Mellai, M., Piazzi, A., Casalone, C., et al. Astroblastoma: beside being a tumor entity, an occasional phenotype of astrocytic gliomas?. Onco Targets Ther 8 (2015), 451–460.
12. 12 Fuller, G.N., Scheithauer, B.W., The 2007 Revised World Health Organization (WHO) Classification of Tumours of the Central Nervous System: newly codified entities. Brain Pathol 17 (2007), 304–307.
13. 13 Sughrue, M.E., Choi, J., Rutkowski, M.J., et al. Clinical features and post-surgical outcome of patients with astroblastoma. J Clin Neurosci 18 (2011), 750–754.
14. 14 Brat, D.J., Hirose, Y., Cohen, K.J., et al. Astroblastoma: clinicopathologic features and chromosomal abnormalities defined by comparative genomic hybridization. Brain Pathol 10 (2000), 342–352.
15. 15 Craig, J.M., Vena, N., Ramkissoon, S., et al. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS ONE, 7, 2012 e38881.
16. 16 Ramkissoon, S.H., Bi, W.L., Schumacher, S.E., et al. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol 17 (2015), 1344–1355.
17. 17 Cryan, J.B., Haidar, S., Ramkissoon, L.A., et al. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget 5 (2014), 8083–8092.
18. 18 Kilday, J.P., Rahman, R., Dyer, S., et al. Pediatric ependymoma: biological perspectives. Mol Cancer Res 7 (2009), 765–786.
19. 19 Witt, H., Mack, S.C., Ryzhova, M., et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20 (2011), 143–157.
20. 20 Mack, S.C., Witt, H., Piro, R.M., et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506 (2014), 445–450.
21. 21 Parker, M., Mohankumar, K.M., Punchihewa, C., et al. C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma. Nature 506 (2014), 451–455.
22. 22 Pajtler, K.W., Witt, H., Sill, M., et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27 (2015), 728–743.
23. 23 Pfister, S.X., Ahrabi, S., Zalmas, L.P., et al. SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. Cell Rep 7 (2014), 2006–2018.
24. 24 Fontebasso, A.M., Schwartzentruber, J., Khuong-Quang, D.A., et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol 125 (2013), 659–669.
25. 25 Hoffman, L.M., DeWire, M., Ryall, S., et al. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics. Acta Neuropathol Commun, 4, 2016, 1.
26. 26 Chiang, C., Ihrie, R.A., Controlling COR competence: BCL-6 regulates neurogenesis and tumor suppression. Cancer Cell 26 (2014), 773–774.
27. 27 Pugh, T.J., Weeraratne, S.D., Archer, T.C., et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488 (2012), 106–110.
28. 28 Tiberi, L., Bonnefont, J., van den Ameele, J., et al. A BCL6/BCOR/SIRT1 complex triggers neurogenesis and suppresses medulloblastoma by repressing Sonic Hedgehog signaling. Cancer Cell 26 (2014), 797–812.
29. 29 Ramkissoon, L.A., Horowitz, P.M., Craig, J.M., et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci USA 110 (2013), 8188–8193.
30. 30 Zhang, J., Wu, G., Miller, C.P., et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45 (2013), 602–612.
31. 31 Wibom, C., Sjostrom, S., Henriksson, R., et al. DNA-repair gene variants are associated with glioblastoma survival. Acta Oncol 51 (2012), 325–332.
32. 32 Xiang, F., Tanaka, J., Takahashi, J., et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors in diffusely infiltrating astrocytomas and relationship to proliferative activity of tumor cells. Brain Tumor Pathol 18 (2001), 67–71.
33. 33 Lewis-Tuffin, L.J., Feathers, R., Hari, P., et al. Src family kinases differentially influence glioma growth and motility. Mol Oncol 9 (2015), 1783–1798.
34. 34 Li, Y., Fu, S.Y., Wang, L.H., et al. Copper improves the anti-angiogenic activity of disulfiram through the EGFR/Src/VEGF pathway in gliomas. Cancer Lett 369 (2015), 86–96.
35. 35 Park, E., Kim, N., Ficarro, S.B., et al. Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Nat Struct Mol Biol 22 (2015), 703–711.
36. 36 Chang, J.H., Hwang, Y.H., Lee, D.J., et al. MicroRNA-203 modulates the radiation sensitivity of human malignant glioma cells. Int J Radiat Oncol Biol Phys 94 (2016), 412–420.
37. 37 Ahmed, K.A., Allen, P.K., Mahajan, A., et al. Astroblastomas: a Surveillance, Epidemiology, and End Results (SEER)-based patterns of care analysis. World Neurosurg 82 (2014), e291–e297.
38. 38 Bi, W.L., Beroukhim, R., Beating the odds: extreme long-term survival with glioblastoma. Neuro Oncol 16 (2014), 1159–1160.
39. 39 Gerber, N.K., Goenka, A., Turcan, S., et al. Transcriptional diversity of long-term glioblastoma survivors. Neuro Oncol 16 (2014), 1186–1195.